Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients

References

• Calzadilla BertotLAdamsLAThe natural course of non-alcoholic fatty liver diseaseInt J Mol Sci2016175774
   PubMed Web of Science ®Google Scholar
• YounossiZMKoenigABAbdelatifDFazelYHenryLWymerMGlobal epidemiology of non-alcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence and outcomesHepatology2016641738426707365
   PubMed Web of Science ®Google Scholar
• KalraSVithalaniMGulatiGStudy of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT)J Assoc Physicians India201361744845324772746
   PubMedGoogle Scholar
• TolmanKGDalpiazASTreatment of non-alcoholic fatty liver diseaseTher Clin Risk Manag2007361153116318516264
   PubMedGoogle Scholar
• ValentiLBugianesiEPajvaniUTargherGNonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?Liver Int201636111563157927276701
   PubMed Web of Science ®Google Scholar
• DongiovanniPAnsteeQMValentiLGenetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatmentCurr Pharm Des201319295219523823394097
   PubMed Web of Science ®Google Scholar
• LiLLiuDWYanHYWangZYZhaoSHWangBObesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studiesObes Rev201617651051927020692
   PubMed Web of Science ®Google Scholar
• MakrisAFosterGDDietary approaches to the treatment of obesityPsychiatr Clin North Am201134481382722098806
   PubMed Web of Science ®Google Scholar
• DajaniAAbuHammourATreatment of nonalcoholic fatty liver disease: where do we stand? an overviewSaudi J Gastroenterol20162229110526997214
   PubMed Web of Science ®Google Scholar
• FilippatosTDDerdemezisCSGaziIFNakouESMikhailidisDPElisafMSOrlistat-associated adverse effects and drug interactions: a critical reviewDrug Saf2008311536518095746
   PubMed Web of Science ®Google Scholar
• AthyrosVGGioulemeOGanotakisESSafety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyArch Med Sci20117579680522291824
   PubMed Web of Science ®Google Scholar
• HarrisonSFinckeCHelinskiDTorgersonSHayashiPA pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patientsAliment Pharmacol Ther200420662362815352910
   PubMed Web of Science ®Google Scholar
• HusseinOGrosovskiMSchlesingerSSzvalbSAssyNOrlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH)Dig Dis Sci200752102512251917404856
   PubMed Web of Science ®Google Scholar
• Zelber-SagiSKesslerABrazowskyEA double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver diseaseClin Gastroenterol Hepatol20064563964416630771
   PubMed Web of Science ®Google Scholar
• LuYLiuXJiaoYPeriostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARαJ Clin Invest201412483501351325003192
   PubMed Web of Science ®Google Scholar
• HuangYLiuWXiaoHMatricellular protein periostin contributes to hepatic inflammation and fibrosisAm J Pathol2015185378679725541330
   PubMed Web of Science ®Google Scholar
• AmaraSLopezKBananBSynergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosisMol Immunol2015641263525467797
   PubMed Web of Science ®Google Scholar
• ZhuJZZhuHTDaiYNSerum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case–control studyEndocrine20165119110026362060
   PubMed Web of Science ®Google Scholar
• FinelliCTarantinoGWhat is the role of adiponectin in obesity related non-alcoholic fatty liver disease?World J Gastroenterol201319680281223430039
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPSahebkarAImprovement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysisBr J Clin Pharmacol201681581983426717446
   PubMed Web of Science ®Google Scholar
• ValentiLRamettaRRuscicaMThe I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controlsBMC Gastroenterol201212111122898488
   PubMed Web of Science ®Google Scholar
• WieckowskaAPapouchadoBGLiZLopezRZeinNNFeldsteinAEIncreased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitisAm J Gastroentero2008103613721379
   PubMed Web of Science ®Google Scholar
• BastardJPMaachiMLagathuCRecent advances in the relationship between obesity, inflammation, and insulin resistanceEur Cytokine Netw200617141216613757
   PubMed Web of Science ®Google Scholar
• WullaertAvan LooGHeyninckKBeyaertRHepatic tumor necrosis factor signaling and nuclear factor-κB: effects on liver homeostasis and beyondEndocr Rev200728436538617431229
   PubMed Web of Science ®Google Scholar
• Flechtner-MorsMGeorgeSNOeztuerkSAssociation of adiponectin with hepatic steatosis: a study of 1,349 subjects in a random population sampleBMC Res Notes2014720724693952
   PubMedGoogle Scholar
• World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJAMA2013310202191219424141714
   PubMed Web of Science ®Google Scholar
• von ElmEAltmanDGEggerMPocockSJGotzschePCVandenbrouckeJPThe strengthening the reporting of observational studies in epidemiology [STROBE] statement: guidelines for reporting observational studiesGaceta sanitaria/S.E.S.P.A200822144150 Spanish
   PubMed Web of Science ®Google Scholar
• MatthewsDHoskerJRudenskiANaylorBATreacherDFTurnerRCHomeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia19852874124193899825
   PubMed Web of Science ®Google Scholar
• RozaAMShizgalHMThe Harris Benedict equation reevaluated: resting energy requirements and the body cell massAm J Clin Nutr19844011681826741850
   PubMed Web of Science ®Google Scholar
• ScatarigeJCScottWWDonovanPJSiegelmanSSSandersRCFatty infiltration of the liver: ultrasonographic and computed tomographic correlationJ Ultrasound Med1984319146694259
   PubMed Web of Science ®Google Scholar
• AnguloPHuiJMMarchesiniGThe NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLDHepatology200745484685417393509
   PubMed Web of Science ®Google Scholar
• HarrisonSAOliverDArnoldHLGogiaSNeuschwander-TetriBADevelopment and validation of a simple NALFD clinical scoring system for identifying patient without advanced diseaseGut200857101441144718390575
   PubMed Web of Science ®Google Scholar
• HarrisonSAFechtWBruntEMNeuschwander-TetriBAOrlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trialHepatology2009491808619053049
   PubMed Web of Science ®Google Scholar
• EspositoKPontilloADi PaloCEffect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trialJAMA2003289141799180412684358
   PubMed Web of Science ®Google Scholar
• PanJJFallonMBGender and racial differences in nonalcoholic fatty liverWorld J Hepatol20146527428324868321
   PubMedGoogle Scholar
• LuoYQuHWangHPlasma periostin levels are increased in Chinese subjects with obesity and type 2 diabetes and are positively correlated with glucose and lipid parametersMediators Inflamm20162016642363727313402
   PubMed Web of Science ®Google Scholar
• DixonANValsamakisGHanifMWEffect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose toleranceInt J Clin Pract20086271124112918564278
   PubMed Web of Science ®Google Scholar
• LewWYBaynaEMolleEDRecurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in micePLoS One201384e6105723585870
   PubMed Web of Science ®Google Scholar
• HsiaoTJWuLSHuangSYLinEA common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesityClin Pharmacol2010210511022291493
   PubMedGoogle Scholar
• YangWSLeeWJFunahashiTWeight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectinJ Clin Endocrinol Metab20018683815381911502817
   PubMed Web of Science ®Google Scholar